Imaging perfusion and hypoxia with PET to predict radiotherapy response in head-and-neck cancer

International Journal of Radiation Oncology Biology Physics

Volumn 59, Issue 4, 2004, Pages 971-982

  Lehtiö, Kaisa ^a   Eskola, Olli ^a   Viljanen, Tapio ^a   Oikonen, Vesa ^a   Grönroos, Tove ^b   Sillanmäki, Lauri ^c   Grénman, Reidar ^a   Minn, Heikki ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

Author keywords

Blood flow; FETNIM; Head and neck cancer; Hypoxia; PET

Indexed keywords

BLOOD; CELLS; METABOLISM; ONCOLOGY; POSITRON EMISSION TOMOGRAPHY; TUMORS;

BLOOD FLOW; BLOOD SUPPLY; FRACTIONAL HYPOXIC VOLUME (FHV);

RADIOTHERAPY;

CISPLATIN; FLUORODEOXYGLUCOSE F 18; FLUOROERYTHRONITROIMIDAZOLE F 18; FLUOROURACIL; TRACER; UNCLASSIFIED DRUG; WATER O 15;

ADULT; AGED; ARTICLE; AUTORADIOGRAPHY; BEAM THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG UPTAKE; FEMALE; HEAD CANCER; HODGKIN DISEASE; HUMAN; HYPOXIA; IMAGING; MALE; MATHEMATICAL COMPUTING; NECK CANCER; NECK DISSECTION; OXYGENATION; PERFUSION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; TREATMENT OUTCOME; TUMOR BLOOD FLOW; TUMOR VOLUME;

ADULT; AGED; CELL HYPOXIA; FEMALE; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NITROIMIDAZOLES; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT OUTCOME;

EID: 3042518844     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2003.12.014     Document Type: Article

References (51)

1. Adams G.L. Treatment of head and neck cancer with combined modalities. Invest Radiol. 24:1989;562-567
2. Haffty B.G. Concurrent chemoradiation in the treatment of head and neck cancer. Hematol Oncol Clin North Am. 13:1999;719-742
3. Browman G.P., Hodson D.I., Mackenzie R.J., et al. Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer A systematic review of the published literature with subgroup analysis. Head Neck. 23:2001;579-589
4. Sanderson R.J., Ironside J.A. Squamous cell carcinomas of the head and neck. BMJ. 325:2002;822-827
5. Hall E.J. Radiosensitizers and bioreductive drugs. Hall E.J. Radiobiology for the radiologist. 1994;165-181 JB Lippincott, Philadelphia
6. Lutterbach J., Guttenberger R. Anemia is associated with decreased local control of surgically treated squamous cell carcinomas of the glottic larynx. Int J Radiat Oncol Biol Phys. 48:2000;1345-1350
7. Brown J.M. Exploiting the hypoxic cancer cell Mechanisms and therapeutic strategies. Mol Med Today. 6:2000;157-162
8. Mankoff D.A., Dunnwald L.K., Gralow J.R., et al. Blood flow and metabolism in locally advanced breast cancer Relationship to response to therapy. J Nucl Med. 43:2002;500-509
9. Hermans R., Lambin P., van der G.A., et al. Tumoural perfusion as measured by dynamic computed tomography in head and neck carcinoma. Radiother Oncol. 53:1999;105-111
10. Vaupel P., Kallinowski F., Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors A review. Cancer Res. 49:1989;6449-6465
11. Folkman J., Watson K., Ingber D., et al. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature. 339:1989;58-61
12. Gillies R.J., Schornack P.A., Secomb T.W., et al. Causes and effects of heterogeneous perfusion in tumors. Neoplasia. 1:1999;197-207
13. Hlatky L., Hahnfeldt P., Folkman J. Clinical application of antiangiogenic therapy Microvessel density, what it does and doesn't tell us. J Natl Cancer Inst. 94:2002;883-893
14. Denekamp J. Review article Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol. 66:1993;181-196
15. Chapman J.D., Engelhardt E.L., Stobbe C.C., et al. Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays. Radiother Oncol. 46:1998;229-237
16. Koh W.J., Bergman K.S., Rasey J.S., et al. Evaluation of oxygenation status during fractionated radiotherapy in human non-small-cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys. 33:1995;391-398
17. 18F] fluoromisonidazole A pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys. 36:1996;417-428
18. Nunn A., Linder K., Strauss H.W. Nitroimidazoles and imaging hypoxia. Eur J Nucl Med. 22:1995;265-280
19. 18F]FETNIM A potential marker for PET. J Nucl Med. 42:2001;1397-1404
20. Yang D.J., Wallace S., Cherif A., et al. Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia. Radiology. 194:1995;795-800
21. 18F- fluoroerythronitroimidazole radiation dosimetry in cancer studies. J Nucl Med. 43:2002;1674-1680
22. 18F]fluoroerythronitroimidazole PET. J Nucl Med. 42:2001;1643-1652
23. 2O production system for heart and brain studies. J Labelled Compounds Radiopharm. 44:(Suppl. 1):2001;S1066-S1068
24. 18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med. 27:1986;235-238
25. DeGrado T.R., Turkington T.G., Williams J.J., et al. Performance characteristics of a whole-body PET scanner. J Nucl Med. 35:1994;1398-1406
26. Bergström M., Eriksson L., Bohm C., et al. Correction for scattered radiation in a ring detector positron camera by integral transformation of the projections. J Comput Assist Tomogr. 7:1983;42-50
27. Huang S.C. Anatomy of SUV. Nucl Med Biol. 27:2000;643-646
28. Zasadny K.R., Kison P.V., Francis I.R., et al. FDG-PET Determination of metabolically active tumor volume and comparison with CT. Clin Positron Imag. 1:1998;123-129
29. Kahn D., Weiner G.J., Ben Haim S., et al. Positron emission tomographic measurement of bone marrow blood flow to the pelvis and lumbar vertebrae in young normal adults. [published erratum in Blood 1994;84:3602] Blood. 83:1994;958-963
30. Nordsmark M., Bentzen S.M., Overgaard J. Measurement of human tumour oxygenation status by a polarographic needle electrode An analysis of inter- and intratumour heterogeneity. Acta Oncol. 33:1994;383-389
31. Valavaara R., Aitasalo K., Kulmala J., et al. Is high dose preoperative hyperfractionated accelerated radiotherapy feasible in the treatment of advanced head and neck squamous cell carcinoma? [Abstract] Radiother Oncol. 57:(Suppl):2001;S99-S100
32. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481
33. Overgaard J., Horsman M.R. Overcoming hypoxic cell radioresistance. Steel G.G. Basic clinical radiobiology for radiation oncologists. 1993;163-172 Edward Arnold Publishers, New York
34. Brown J.M., Giaccia A.J. The unique physiology of solid tumors Opportunities (and problems) for cancer therapy. Cancer Res. 58:1998;1408-1416
35. Nordsmark M., Loncaster J., Chou S.C., et al. Invasive oxygen measurements and pimonidazole labeling in human cervix carcinoma. Int J Radiat Oncol Biol Phys. 49:2001;581-586
36. Raleigh J.A., Chou S.C., Arteel G.E., et al. Comparisons among pimonidazole binding, oxygen electrode measurements, and radiation response in C3H mouse tumors. Radiat Res. 151:1999;580-589
37. Nordsmark M., Overgaard M., Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol. 41:1996;31-39
38. Brizel D.M., Scully S.P., Harrelson J.M., et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 56:1996;941-943
39. 18F]-2-fluoro-2-deoxy-D-glucose and positron emission tomography An overview of different analytical methods. Eur J Nucl Med. 27:2000;731-743
40. Hany T.F., Steinert H.C., Goerres G.W., et al. PET diagnostic accuracy Improvement with in-line PET-CT system - Initial results. Radiology. 225:2002;575-581
41. Chung J.K., Chang Y.S., Lee Y.J., et al. The effect of tumor size on F-18-labeled fluorodeoxyglucose and fluoroerythronitroimidazole uptake in a murine sarcoma model. Ann Nucl Med. 13:1999;303-308
42. 18F]FMISO in an experimental mammary carcinoma. Eur J Nucl Med Mol Imaging 2004;31:513-520
43. Hoekstra C.J., Stroobants S.G., Hoekstra O.S., et al. Measurement of perfusion in stage IIIA-N2 non-small cell lung cancer using H(2)(15)O and positron emission tomography. Clin Cancer Res. 8:2002;2109-2115
44. Hochberg Y., Tamhane A.C. Multiple comparison procedures. 1987;John Wiley & Sons, New York
45. Lammertsma A.A., Jones T. Low oxygen extraction fraction in tumours measured with the oxygen-15 steady state technique Effect of tissue heterogeneity. Br J Radiol. 65:1992;697-700
46. Beaney R.P., Lammertsma A.A., Jones T., et al. Positron emission tomography for in-vivo measurement of regional blood flow, oxygen utilisation, and blood volume in patients with breast carcinoma. Lancet. 1:1984;131-134
47. Wilson C.B., Lammertsma A.A., McKenzie C.G., et al. Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography A rapid and noninvasive dynamic method. Cancer Res. 52:1992;1592-1597
48. 18F-fluoromisonidazole PET and polarographic needle electrodes in human soft tissue tumours. Radiother Oncol 2003;67:339-344
49. 18F]FETNIM) and PET using the tumour to plasma ratio. Eur J Nucl Med. 30:2003;101-108
50. Ponto L., Madsen M.T., Hichwa R.D., et al. Assessment of blood flow in solid tumors using PET. Clin Positron Imag. 1:1998;117-121
51. Rischin D., Peters L., Hicks R., et al. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J Clin Oncol. 19:2001;535-542